Investing.comQwen · 实盘不做把握 3/10不做原因:已被定价
北京时间·🕒 发布 19:08:41·⟳ 抓取 19:09:30 +49s·⚡ 决策 09-03 19:13:13 +3m43s·54.1 天前
Eledon Pharmaceuticals向FDA提交tegoprubart胰岛细胞移植注册性临床试验IND申请
IND提交是Q2财报已明确预告的执行步骤，底层临床数据(12/12胰岛素独立)自2026年3月起已公开，不构成新增信息差；股价处于持续下行趋势(13周指数从100跌至84)，先例显示Q2财报(含同一预告)后5日跌5.8%；流动性极差(买卖价差23%、盘前仅241股成交)，无法有效执行
📄 原文Investing.com↗ 原文
Eledon submits IND for tegoprubart islet cell transplant study
Oil pulls back, Broadcom disappoints - what’s moving markets IRVINE, Calif. - Eledon Pharmaceuticals Inc. (NASDAQ:ELDN)…
不做 Eledon Pharmaceuticals（ELDN.US）
IND提交是Q2财报已明确预告的执行步骤，无新增预期差；底层数据自3月起已公开；股价处于持续下行趋势(13周-16%)；先例显示同类催化后股价负面反应(-5.8%/5日)；流动性极差(买卖价差23%、盘前仅241股)无法有效执行
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Eledon于2026年9月3日提交tegoprubart胰岛细胞移植注册性试验IND，但该计划已在8月13日Q2财报中明确列为即将启动的里程碑，底层12/12胰岛素独立数据自3月起多次公开。股价近13周持续下行(-35%距52周高)，先例显示同类催化后股价负面反应。盘前仅+2.3%且成交241股，买卖价差达23%，无有效执行条件。综合判断无增量预期差，不做。
🔎 新鲜度:最早出现 2026-09-03 · 扩散 low · price-in 风险 high ↗
主要风险
- IND提交本身不改变近期收入前景，公司现金从$133.3M降至$88.8M且Phase 3将加速烧钱，存在稀释风险
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-08-13 · 影响 weakens
现金从$133.3M降至$88.8M(6个月烧$44.5M)，净亏损$31.6M/季，现金仅支撑到2027年Q2；Phase 3启动将加速烧钱，稀释风险高
检索:Eledon ELDN stock decline cash dilution risk 2026 原文 ↗ - 做多前查反向 · 来源 kb_search · 日期 2026-03-24 · 影响 none
Guggenheim维持BUY/$8目标价，但股价持续下行至$3说明市场不认可远期估值；买方观点不改变短期无催化的事实
检索:Eledon tegoprubart analyst rating target price 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例确认ELDN对已预告的监管里程碑无正面定价，强化了AVOID判断；不改变方向但降低了任何做多可能性
方向:ELDN对同类临床/监管催化的反应偏负面或中性：ADA数据展示后+3日超额-4.9%，Q2财报(含同一预告)后5日跌5.8%
涨幅量级:无高相似先例(相似度均<8)；Q2财报(相似度7)显示含同一预告的催化后股价持续下行，不支持正面幅度预期
形态:Q2财报前5日涨9.6%后事件日即转跌，呈典型'买预期卖事实'；本次IND提交作为该预告的执行，更无新增催化力
历史先例(按相似度)
- 相似度 7/10 ELDN 2026-08-13 Eledon Q2 2026财报，已预告将启动胰岛细胞移植注册路径研究，现金$88.8M 原文 ↗
事件后 +1日 -1.9% · +2日 -6.1% · +3日 -5.0% · +4日 -4.0% · +5日 -5.8%
⚠未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同公司同药物，Q2财报已包含本次IND提交的预告，是最直接的前置催化
经验:Q2财报含注册路径预告后股价5日跌5.8%，超额-5.4%，市场对该计划无正面定价 - 相似度 6/10 ELDN 2026-06-11 Eledon在ADA 2026展示12/12胰岛素独立数据，市值约$280M 原文 ↗
事件后 +1日 +3.2% · +2日 +3.2% · +3日 -0.9% · +4日 +0.6% · +5日 +6.9%
⚠未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同公司同药物同适应症数据展示，但事件类型(数据展示)与当前(IND提交)不同
经验:ADA数据展示后+1日涨3.2%但+3日转跌，超额收益-4.9%，市场对已知数据反应有限
工具执行结果 · 成功 8 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 356 ms
{"result": "search_processed_events:agent query=`eldn tegoprubart type 1 diabetes registrational trial | eledon fda ind submission | eledon pharmaceuticals ind tegoprubart islet cell transplant`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、7366 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重 - stock_quote 成功 stock_tools HTTP · 1,536 ms
{ - fetch_decision_experience 成功 stock_tools HTTP · 18 ms
{ - search_case_library 成功 stock_tools HTTP · 20 ms
{"result": "search_case_library「ELDN.US」无历史决策命中(我们过去没在这些标的上决策过,或历史尚未回填)。\n◆ ELDN.US：相关历史决策 0 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过"} - kb_search 成功 stock_tools HTTP · 1,005 ms
{ - kb_fetch_document 成功 stock_tools HTTP · 37 ms
{ - kb_search 成功 stock_tools HTTP · 442 ms
{ - event_study 成功 stock_tools HTTP · 21 ms
{
原文全文
展开原文 · 2,365 字
Oil pulls back, Broadcom disappoints - what’s moving markets
IRVINE, Calif. - Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a registrational clinical trial evaluating tegoprubart in type 1 diabetes patients undergoing pancreatic islet cell transplantation, according to a company press release issued today.
The planned study would be Eledon’s first company-sponsored clinical trial in islet cell transplantation. The company’s anti-CD40L antibody tegoprubart is being developed as an immunosuppression therapy for transplant patients.
The first patients have been enrolled in an investigator-initiated clinical trial at the University of Chicago Medicine Transplant Institute evaluating tegoprubart in patients with type 1 diabetes and renal dysfunction from chronic kidney disease receiving an islet cell transplant. The study examines a calcineurin inhibitor-free, tegoprubart-based immunosuppression regimen.
The first islet cell transplant recipient has been dosed with tegoprubart under a compassionate-use protocol to switch from tacrolimus-based immunosuppression therapy due to calcineurin inhibitor-related renal dysfunction.
UChicago Medicine is adding three patients to its ongoing investigator-initiated islet cell transplantation study, expanding beyond the 12 patients treated to date. Previously reported results showed all 12 patients with type 1 diabetes achieved insulin independence and a hemoglobin A1c level below 7.0% following islet cell transplantation and treatment with tegoprubart, with stable islet graft function observed through a maximum reported follow-up of 22 months.
In kidney transplantation, the first highly sensitized kidney transplant patient has been dosed with tegoprubart under a compassionate-use protocol at Duke University Medical Center. A third patient has been treated in an investigator-initiated study evaluating tegoprubart for kidney transplant tolerance induction at Massachusetts General Hospital.
Eledon stated it remains on track to initiate its global Phase 3 LEGACY trial of tegoprubart in kidney transplantation in the fourth quarter of 2026. The trial is expected to enroll approximately 600 patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
IRVINE, Calif. - Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a registrational clinical trial evaluating tegoprubart in type 1 diabetes patients undergoing pancreatic islet cell transplantation, according to a company press release issued today.
The planned study would be Eledon’s first company-sponsored clinical trial in islet cell transplantation. The company’s anti-CD40L antibody tegoprubart is being developed as an immunosuppression therapy for transplant patients.
The first patients have been enrolled in an investigator-initiated clinical trial at the University of Chicago Medicine Transplant Institute evaluating tegoprubart in patients with type 1 diabetes and renal dysfunction from chronic kidney disease receiving an islet cell transplant. The study examines a calcineurin inhibitor-free, tegoprubart-based immunosuppression regimen.
The first islet cell transplant recipient has been dosed with tegoprubart under a compassionate-use protocol to switch from tacrolimus-based immunosuppression therapy due to calcineurin inhibitor-related renal dysfunction.
UChicago Medicine is adding three patients to its ongoing investigator-initiated islet cell transplantation study, expanding beyond the 12 patients treated to date. Previously reported results showed all 12 patients with type 1 diabetes achieved insulin independence and a hemoglobin A1c level below 7.0% following islet cell transplantation and treatment with tegoprubart, with stable islet graft function observed through a maximum reported follow-up of 22 months.
In kidney transplantation, the first highly sensitized kidney transplant patient has been dosed with tegoprubart under a compassionate-use protocol at Duke University Medical Center. A third patient has been treated in an investigator-initiated study evaluating tegoprubart for kidney transplant tolerance induction at Massachusetts General Hospital.
Eledon stated it remains on track to initiate its global Phase 3 LEGACY trial of tegoprubart in kidney transplantation in the fourth quarter of 2026. The trial is expected to enroll approximately 600 patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。